Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Life Sciences, Pillar Biosciences Partner to Develop NGS Solutions

NEW YORK – Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions. 

Under the agreement, Pillar will develop applications designed for Beckman Coulter's Biomek NGenius System, an automated library preparation platform that includes a reagent input carousel, an integrated thermal cycler, and a labware transport system. The applications developed will be available to all users via an electronic application library, Danaher subsidiary Beckman Coulter said in a statement.

Financial and other terms of the agreement were not disclosed. 

Pillar Biosciences will use the system to develop applications for its portfolio of OncoReveal tests, which use Pillar's single-tube enrichment chemistry. The firm currently offers more than 20 NGS-based testing products that are available in in vitro diagnostic or research-use-only formats, including its OncoReveal Dx Lung and Colon Cancer Assay, which received approval from the US Food and Drug Administration last year. It also has a pan-cancer OncoReveal companion diagnostic test in development. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.